Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2000, p. 2406-2410, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Sodium Stibogluconate (Pentostam) Potentiates
Oxidant Production in Murine Visceral Leishmaniasis and in
Human Blood
Samira
Rais,1,2
Axel
Perianin,3
Monique
Lenoir,3
Abderrahim
Sadak,4
Daniele
Rivollet,1
Muriel
Paul,5 and
Michele
Deniau1,*
Service de Parasitologie, Faculté de
Médecine,1 and Service de
Pharmacie,5 CHU Henri Mondor, 94010 Créteil, and CNRS UPRES-A 8068, Pharmacologie,
Hôpital Cochin, 75014 Paris,3 France, and
Laboratoire de Parasitologie, Faculté des Sciences,
Rabat,4 and Laboratoire de
Biochimie, Faculté des Sciences Ben M'sik,
Casablanca,2 Morocco
Received 7 February 2000/Returned for modification 5 April
2000/Accepted 7 June 2000
 |
ABSTRACT |
Sodium stibogluconate (Sbb), a leishmanicidal drug, was studied for
its in vivo effect on the formation of reactive oxygen species (ROS),
assessed by chemiluminescence (CL) in the whole blood of mice infected
with Leishmania infantum. Stimulation of ROS formation
induced ex vivo by zymosan particles or the protein kinase C activator
phorbol myristate acetate (PMA) was reduced by approximately 25%
(P < 0.05) after infection of mice. Treatment of
infected mice with Sbb (50 to 400 mg/kg of body weight) enhanced the
blood CL induced by zymosan and PMA (47 to 96%, P < 0.01). The drug potentiation effect also occurred in uninfected mice. In vitro treatment of normal human blood with Sbb (1, 10, or 100 µg/ml) for 1 h primed the CL response to PMA (29 to 54%). The priming effect of Sbb was also observed on the production of superoxide by isolated polymorphonuclear leukocytes stimulated either by PMA and
zymosan or by the chemoattractants N-formyl-Met-Leu-Phe and
platelet-activating factor. These data provide the first evidence of
priming of the phagocyte respiratory burst by Sbb. This novel property
of Sbb may contribute to the drug's leishmanicidal effect.
 |
INTRODUCTION |
Stimulation of phagocytes
(polymorphonuclear cells, monocytes, and macrophages) by particle
agents or soluble mediators such as chemoattractants triggers the
generation of large amounts of superoxide anion
(O2·) and related reactive oxygen species
(ROS), such as hydrogen peroxide (H2O2) and
hydroxyl radicals (OH·) and singlet oxygen
(1O2). This generation, termed respiratory
burst, plays a major role in the destruction of invading pathogens by
phagocytes (4). In certain circumstances, the phagocyte
respiratory burst is enhanced after cell treatment with low
concentrations of certain agonists or drugs. This phenomenon, termed
"priming" (14), may have beneficial or detrimental
biological effects. Leishmania is a parasite of macrophages
that causes a broad range of diseases, including cutaneous, mucocutaneous, and acute visceral leishmaniasis (27). It has been proposed that activated macrophages kill intracellular parasites by generating ROS and nitric oxide (20, 22, 27, 30).
Visceral leishmaniasis is associated with depression of immune
defenses, and Leishmania spp. appear to be resistant to
oxygen-dependent toxicity (8, 17). al-Mofleh et al. have
shown that the phagocyte respiratory burst was down-regulated in
animals receiving antigens of Leishmania major
(2). These antigens were also found to inhibit the
respiratory burst of isolated polymorphonuclear leukocytes (PMN) in
vitro (3). The importance of PMN in the early control of
parasite load and spreading of parasitism in cutaneous leishmaniasis was recently reported (21).
Pentavalent antimonials, available as sodium stibogluconate (Pentostam)
(Sbb) or meglumine antimoniate (Glucantime), are the first-choice
therapy for visceral leishmaniases of immunocompetent patients but
appear to be inefficacious in immunocompromised patients. Moreover,
some authors have suggested that nonspecific cell defense was required
for a completely successful cure (17). These drugs were
shown to interact with Leishmania and inhibit its viability in vitro (6). However, the effects of these drugs on host
cell reactivity and their mode of action are not fully understood. To
gain insight into the mechanism of Sbb's leishmanicidal effect, we
studied the in vivo drug effect on the generation of ROS, as measured
by luminol-dependent chemiluminescence (CL) assay in the whole blood of
Leishmania infantum-infected and uninfected mice. We further
analyzed the effects of Sbb in vitro on the CL response of whole blood
of healthy volunteers and on the production of superoxide anion by
purified PMN stimulated by various agents.
 |
MATERIALS AND METHODS |
Reagents.
Dextran T500 was from Pharmacia (Uppsala, Sweden),
and other reagents were from the Sigma Chemical Co. (St. Louis, Mo.).
Stock solutions of N-formyl-Met-Leu-Phe (fMLP),
platelet-activating factor (PAF), and phorbol myristate acetate (PMA)
were prepared in dimethyl sulfoxide. Zymosan particles were opsonized
by incubating 10 mg of zymosan in 1 ml of human serum for 30 min at
37°C. The zymosan suspension was washed twice in phosphate-buffered
saline and used at a final concentration of 0.5 mg/ml. A stock solution of Sbb (Wellcome, London, United Kingdom) was used at a concentration of 100 mg/ml in phosphate-buffered saline.
Animals and parasites.
A murine model of visceral
leishmaniasis was used as previously described by Paul et al.
(23). Thirty BALB/c mice were infected intravenously on day
0 with 107 stationary-phase promastigotes of L. infantum MON 1 (MHOM/PT/93/CRE69), identified by the Reference
Center of the World Health Organization (Montpellier, France). The
infected mice were randomly assigned to four groups of five mice, which
were treated subcutaneously with 50, 100, 200, or 400 mg of Sbb/kg of
body weight on days 14, 16, and 18 postinfection. A control group of 10 infected mice received normal saline at the same time. Four groups of 5 uninfected mice received the same Sbb treatment, while 10 uninfected
mice received normal saline.
On day 21 after infection, the mice's blood was collected and
heparinized (10 IU/ml) and the animals were killed by cervical dislocation. Drug efficacy was assessed by evaluating the parasite burden and calculating the 50% effective dose (ED50) and
ED90 according to the Stauber count (28). The
Guiding Principles for Biomedical Research Involving
Animals, published by the Council for International Organizations
of Medical Sciences (Geneva, Switzerland) in 1985, were followed during
all procedures.
PMN preparation.
Human venous blood, heparinized at 10 U/ml,
was obtained from healthy volunteers. PMN were isolated by a first-step
sedimentation of whole blood on 2% dextran T500 followed by
centrifugation of the granulocyte-rich supernatant on a cushion of a
mixture of Ficoll and Hypaque (Eurobio, Les Ulis, France) as previously
described (26). The purified PMN (97%) were subjected to
hypotonic lysis, washed, and resuspended in Hanks balanced salt
solution (HBSS) (pH 7.4) containing 10 mM HEPES.
CL assay.
CL, i.e., light that is generated from singlet
oxygen and other molecules, has been used largely to study the
respiratory burst of phagocytes (1, 18, 29). The in vitro CL
response of whole blood (18, 29) was measured at 37°C
using a Bio-orbit or Picolite luminometer, both from Packard. Briefly,
the reaction mixture consisted of 200 µl of heparinized blood diluted
at 1:10 in 100 µl of HBSS containing 10 µM luminol (18).
Light emission was induced by two phagocyte activators, i.e., opsonized
zymosan (0.5 mg/ml) and a direct activator of protein kinase C (PKC), PMA (1 µg/ml). The CL response was recorded at 26-s intervals for 15 min, and the peak value expressed in millivolts was used to assess
differences between the groups. The CL response by purified PMN was
studied with suspensions of 106 cells under conditions
described in the figure legends. Results represent the peak PMN CL and
are expressed in either millivolts or counts per minute.
Superoxide production.
Production of superoxide anion by
purified PMN was studied by continuous monitoring of cytochrome
c reduction (25) using a Perkin-Elmer Lambda 40 spectrophotometer equipped with thermostated (37°C) cuvette holder
and magnetic stirrer. Suspensions of 2 × 106 PMN in 2 ml of HBSS were treated in the absence (control) or presence of Sbb for
1 h at 37°C before stimulation with various agents known to
trigger respiratory burst through different signaling pathways,
including PMA, zymosan particles, and two chemoattractants, fMLP and
PAF (7). Results are presented as nanomoles of superoxide generated by 106 PMN.
Statistics.
Differences in the effects of Sbb in vivo were
assessed using the Mann-Whitney U test. Differences of the in vitro
drug effects were assessed using Student's t test.
P values of <0.05 were considered statistically significant.
 |
RESULTS |
ROS production in a murine model of leishmaniasis and in vivo
effect of Sbb.
The influence of leishmaniasis on ROS formation was
determined in vitro by comparing the CL responses of the whole blood of infected and uninfected mice. The peak CL response (mean ± standard deviation) induced by PMA or zymosan in the blood of
uninfected animals was, respectively, 0.69 ± 0.04 or 1.44 ± 0.8 mV, whereas that induced in the blood of infected mice was
significantly depressed (P <0.05), by 22 or 27%,
respectively (i.e., 0.54 ± 0.04 or 1.06 ± 0.04 mM).
Treatment of infected animals with various doses of Sbb (50, 100, 200, and 400 mg/kg) induced a strong leishmanicidal effect, as determined by
the Stauber count (28); the ED50 and ED90 were approximately 38 and 164 mg of Sbb/kg, respectively.
The in vivo effect of Sbb on the blood CL response of
Leishmania-infected animals was evaluated next (Fig.
1). The CL response
induced by PMA in the
blood of animals treated with 50, 100, 200,
or 400 mg of Sbb/kg was
significantly enhanced by 46, 57, 98,
or 114%, respectively, relative
to that of the control (0.54 ±
0.04 mV). A similar priming effect
of Sbb (
P, <0.01) was also
observed in the blood of animals
treated with 50, 100, 200, or
400 mg of Sbb/kg after opsonized zymosan
stimulation of the CL
response: 31, 41, 64, or 89%, respectively,
compared to the control
(1.06 ± 0.04 mV). The CL response of the
blood of uninfected mice
measured in the absence of stimuli was
approximately 0.8 mV and
was not modified by treatment with Sbb (data
not shown). The potentiating
in vivo effect of Sbb on the CL response
might be due to the decreased
parasite burden or to an independent
mechanism. To further clarify
this point, the in vivo effect of Sbb on
the CL response of the
blood from uninfected mice was also studied.
Treatment of mice
with 100, 200, or 400 mg of Sbb/kg also primed
(
P, <0.01) the
blood CL response induced by both PMA and
zymosan (Fig.
2). However,
a significant
drug effect was observed with the highest Sbb concentrations
(
P,
<0.05).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 1.
In vivo effect of Sbb on CL response of blood from
L. infantum-infected mice. Mice were infected with
Leishmania and treated in the absence (control) or presence
of 50, 100, 200, or 400 mg of Sbb/kg. The CL of whole blood was induced
in vitro with either PMA (1 µg/ml) or opsonized zymosan (0.5 mg/ml).
Values are the means ± standard errors of the means of the peak
CL obtained with at least six animals.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
In vivo effect of Sbb on CL response of blood from
uninfected mice. Uninfected mice were treated with 50, 100, 200, or 400 mg of Sbb/kg or saline (control), and the CL response of whole blood
was induced with PMA (1 µg/ml) or opsonized zymosan (0.5 mg/ml). The
peak CL response represents the means ± standard errors of the
means obtained with six animals.
|
|
To examine whether the potentiated CL response may result from the
possible interaction of trace amounts of Sbb in the circulating
blood
of treated mice with the luminol assay, we investigated
whether the
presence of Sbb in the assays influenced the CL response.
For this
purpose, blood was collected from uninfected mice and
was treated in
vitro with 1 or 10 µg of Sbb/ml for 1 min prior
to stimulation with
PMA. The treatment failed to modify the PMA-induced
CL response of
blood relative to the control (data not shown).
This control experiment
suggests that the potentiating effect
was not due to Sbb interaction
with the luminol-enhanced CL assay.
Taken together, these observations
suggest that Sbb may modify
the reactivity of phagocytes directly or
indirectly.
In vitro effect of Sbb on the respiratory burst of phagocytes from
healthy volunteers.
To further investigate the mode of action of
Sbb, we analyzed the in vitro effects of Sbb on the CL response of
human blood. Human blood was preferred to that of mice since it is
suitable for the purification of large numbers of leukocytes for
further investigation of drug effects in vitro. Among leukocytes, PMN were chosen for further study of the Sbb effect, since this cell type
is a suitable model for clarifying the mode of action of drugs
(11, 13, 24, 26). In addition, PMN were reported to ingest
L. major in vivo and to control the parasite load
(21). Treatment of human blood or purified PMN in vitro for
1 h in the presence of 1, 10, or 100 µg of Sbb/ml significantly
(P, <0.01) enhanced the CL response induced by PMA (Fig.
3). The optimal potentiation of the CL
response of PMN was obtained in the presence of 10 µg of Sbb/ml,
whereas a higher concentration of the drug was less effective. The time
course of cell treatment with 10 µg of Sbb/ml indicated that a
significant drug potentiating effect required at least 30 min of PMN
treatment.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 3.
In vitro effect of Sbb on CL responses of human blood
and isolated PMN. Human blood or PMN were treated for 1 h in the
absence (control) or presence of the indicated concentrations of Sbb.
The CL response was induced with PMA (1 µg/ml) or zymosan (0.5 mg/ml). The peak CL response was measured by using a Packard Picolite
luminometer and represents the means ± standard errors of the
means of four experiments.
|
|
The luminol-enhanced CL response of stimulated PMN results from the
combined stimulation of the production of ROS (respiratory
burst) and
the release of granular content (exocytosis). Peroxidases
released
during this process catalyze the oxidation of luminol
in the presence
of hydrogen peroxide and halide, a reaction in
which light emission is
enhanced. We determined whether the priming
effects of Sbb were due to
enhancement of the activity of the
respiratory burst oxidase by
measuring the generation of superoxide
anion with the cytochrome
c assay. To gain insight into the mode
of action of Sbb, the
PMN respiratory burst was also stimulated
by various agents known to
trigger different intracellular signaling
pathways. Treatment of PMN
with Sbb (0.1, 10, or 100 µg/ml) for
1 h induced a
concentration-dependent increase in the production
of superoxide
induced by PMA (Fig.
4). The priming
effect of Sbb
(
P, <0.05) was also observed in superoxide
production induced
by zymosan particles (Fig.
4) and the two
chemoattractants PAF
(Fig.
4) and fMLP (Fig.
5), although the latter two stimuli were
less potent than PMA and zymosan.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of Sbb on PMA-, zymosan-, and PAF-induced
production of superoxide by PMN. Suspensions of PMN were incubated with
1, 10, or 100 µg of Sbb/ml for 1 h before stimulation with PMA
(0.1 µg/ml), zymosan (0.5 mg/ml), or PAF (10 µM) for 10 min.
Results represent the total amount of superoxide generated per
106 PMN (means of four experiments ± standard errors
of the means).
|
|

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of Sbb on fMLP-induced production of superoxide
by PMN. PMN were treated in the absence (control) or presence of the
indicated concentrations of Sbb for 1 h and stimulated with 0.1 µM fMLP. Results represent the initial rate of production and the
total production of superoxide (means of four experiments ± standard errors of the means).
|
|
The stimulation of the PMN respiratory burst by chemoattractants is
rapid and constant for a few minutes (initial rate) and
is achieved
within approximately 10 min. Any potentiation of the
respiratory burst
may result from priming of the biochemical process
involved in the
activation of the superoxide-generating NADPH
oxidase and/or inhibition
of the terminating process. Priming
agents may modify one or both of
these parameters, as suggested
by comparison of the initial rate of
production and the total
production of superoxide (
11,
25).
Low concentrations of Sbb
(1 and 10 µg/ml) potentiated both
parameters of the respiratory
burst (Fig.
5). However, Sbb was more
active in priming the initial
rate of superoxide generation (linear
part of the response) relative
to the total amount of superoxide
generated. These observations
suggest that the biochemical alterations
induced by Sbb might
predominantly affect the stimulatory rather than
the terminating
biochemical
process.
 |
DISCUSSION |
This study provides evidence that Sbb has an in vivo protective
effect against the down-regulation of the phagocyte respiratory burst
mediated by L. infantum. This property is associated with Sbb's ability to induce a dose-dependent priming of ROS formation in
the whole blood of infected and uninfected animals. The biochemical mechanism of this priming remains to be elucidated. However, the data
suggest that at least two main processes may be involved. First, it has
been previously shown that Sbb interacts directly with
Leishmania and inhibits its survival (6). The
decrease in parasite burden may consequently reduce the down-regulation of phagocyte killing activity, which has been shown to be mediated in
part by Leishmania antigens (2). A second
mechanism is suggested by our data. The enhancement of the
oxygen-dependent defense activity of phagocytes in uninfected mice by
Sbb indicates that Sbb may directly or indirectly alter the state of
phagocyte activation, independent of the parasite burden. This novel
property of Sbb is further supported by the observation that low
concentrations of the drug (1 to 10 µg/ml) induce increases in ROS
formation in normal human blood and by isolated PMN in vitro. This
potentiation also affects the production of superoxide, indicating that
Sbb enhanced the activity of NADPH oxidase, the enzyme that generates superoxide.
Interestingly, the Sbb priming effect occurred at low drug
concentrations similar to those measured in the plasma of patients (5, 9). Furthermore, priming improves the PMN response
induced by various stimuli (fMLP, PAF, and opsonized zymosan) known to stimulate specific membrane receptors which are also present on monocytes and macrophages. This observation suggests that the drug may
also potentiate receptor-mediated immune responses. In this context, a
third mechanism may be also considered; Sbb may enhance the production
of cytokines such as interleukin 3 and gamma interferon, which have
been shown to induce antileishmanial activity via an enhancement of the
oxidative capacity of macrophages (16). Although the
relative contributions of the mechanisms proposed above remain to be
quantified, the potentiation of ROS formation described here suggests
that Sbb may enhance the killing activities of phagocytes and the
intracellular suppression of L. infantum. However, it should
be noted that increased ROS formation may also have deleterious
effects, particularly in some pathologies. In AIDS, ROS production by
PMN was found to enhance virus replication in patient monocytes
(15). Consequently, one may speculate that the enhancement
of viral replication might further decrease the cell-mediated immune
response. This may contribute in part to the failure of Sbb treatment
in AIDS patients.
The mechanism of PMN priming by Sbb is not known. This priming affects
the respiratory burst induced by proinflammatory agents, such as PAF or
fMLP, and thus mimics the effects of other drugs that were previously
described for human PMN (11, 25). One of these,
staurosporine, is a bacterial alkaloid known as a potent inhibitor of
PKC. This agent also stimulates G protein (19) and
phospholipase D (PLD) activity (19, 24) and primes
fMLP-induced PLD activity in a manner that is correlated with the
respiratory burst of PMN (26). Another agent, okadaic acid,
an inhibitor of protein phosphatase 2A, also primes PLD activity
(13) and respiratory bursts (12). In contrast to
the latter two agents, Sbb also potentiated the PMN respiratory burst
induced by PMA, a direct activator of PKC. This suggests that Sbb may
enhance PKC activity or downstream signaling events, such as
phosphorylation of a major oxidase component, p47phox, as previously
shown with staurosporine (10). Furthermore, the observation
that Sbb has a greater priming effect on the rate of induction than on
the total amount of superoxide induced by fMLP suggests that the
biochemical alteration induced by Sbb may preferentially affect early
events of the signaling cascade involved in the production of second messengers by chemoattractant receptors. Among these, PLD activity may
play a major role since it was shown to be correlated with the primed
respiratory burst of PMN (26). Whether Sbb enhances the
generation of ROS and nitric oxide by macrophages is a major point to
be studied in order to understand the mechanism of Sbb's leishmanicidal effect.
In conclusion, Sbb induced a protective in vivo effect against the
down-regulation of phagocyte defense activity mediated by
Leishmania. This novel property appears to be mediated in
part by a direct interaction of Sbb with phagocytes, resulting in a priming of their ability to generate ROS in response to various stimuli. This effect may contribute to the drug's leishmanicidal property.
 |
ACKNOWLEDGMENTS |
This work is support by Sidaction (Fondation pour la Recherche
Médicale).
We thank the staff of the blood bank of the St. Vincent Hospital for
providing blood samples.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Parasitologie, Faculté de Médecine de Créteil, 8, rue
du Général Sarrail, 94010 Créteil, France. Phone:
(33) 1 49 81 36 31. Fax: (33) 1 49 81 36 01. E-mail:
deniau{at}univ-paris12.fr.
 |
REFERENCES |
| 1.
|
Allen, R. C.
1986.
Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis.
Methods Enzymol.
133:449-493[Medline].
|
| 2.
|
al-Mofleh, I. A.,
A. A. Mahmoud,
A. S. al-Khuwaiter, and A. S. al-Tuwaijri.
1989.
Effect of Leishmania major on luminol-dependent chemiluminescence of human whole blood phagocytosis.
Trop. Med. Parasitol.
40:279-284[Medline].
|
| 3.
|
al Tuwaijri, A. S.,
I. A. al Mofleh, and A. A. Mahmoud.
1990.
Effect of Leishmania major on human polymorphonuclear leucocyte function in vitro.
J. Med. Microbiol.
32:189-193[Abstract/Free Full Text].
|
| 4.
|
Babior, B. M.
1978.
Oxygen-dependent microbial killing by phagocytes (first of two parts).
N. Engl. J. Med.
298:659-668[Medline].
|
| 5.
|
Berman, J. D.,
P. C. Melby, and F. A. Neva.
1989.
Concentration of Pentostam in human breast milk.
Trans. R. Soc. Trop. Med. Hyg.
83:784-785[CrossRef][Medline].
|
| 6.
|
Berman, J. D.,
D. Waddell, and B. D. Hanson.
1985.
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
Antimicrob. Agents Chemother.
27:916-920[Abstract/Free Full Text].
|
| 7.
|
Bokoch, G. M.
1995.
Chemoattractant signaling and leukocyte activation.
Blood
86:1649-1660[Free Full Text].
|
| 8.
|
Carvalho, E. M.,
O. Bacellar,
A. Barral,
R. Badaro, and W. D. Johnson, Jr.
1989.
Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.
J. Clin. Investig.
83:860-864.
|
| 9.
|
Chulay, J. D.,
L. Fleckenstein, and D. H. Smith.
1988.
Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Trans. R. Soc. Trop. Med. Hyg.
82:69-72[CrossRef][Medline].
|
| 10.
|
Combadiere, C.,
J. el Benna,
E. Pedruzzi,
J. Hakim, and A. Perianin.
1993.
Stimulation of the human neutrophil respiratory burst by formyl peptides is primed by a protein kinase inhibitor, staurosporine.
Blood
82:2890-2898[Abstract/Free Full Text].
|
| 11.
|
Combadiere, C.,
J. Hakim,
J. P. Giroud, and A. Perianin.
1990.
Staurosporine, a protein kinase inhibitor, up-regulates the stimulation of human neutrophil respiratory burst by N-formyl peptides and platelet activating factor.
Biochem. Biophys. Res. Commun.
168:65-70[CrossRef][Medline].
|
| 12.
|
Djerdjouri, B.,
C. Combadiere,
E. Pedruzzi,
J. Hakim, and A. Perianin.
1995.
Contrasting effects of calyculin A and okadaic acid on the respiratory burst of human neutrophils.
Eur. J. Pharmacol.
288:193-200[CrossRef][Medline].
|
| 13.
|
Djerdjouri, B.,
E. Pedruzzi,
J. Hakim, and A. Perianin.
1994.
Okadaic acid, an inhibitor of type 1 and type 2A phosphatases, modulates the activation of phospholipase D in formyl peptide- and mastoparan-stimulated human neutrophils.
Biochem. Biophys. Res. Commun.
205:1481-1487[CrossRef][Medline].
|
| 14.
|
Hallett, M. B., and D. Lloyds.
1995.
Neutrophil priming: the cellular signals that say 'amber' but not 'green.' Immunol.
Today
16:264-268.
|
| 15.
|
Ho, J.,
S. He,
A. Hu,
J. Geng,
F. Basile,
M. Almeida,
A. Saito,
J. Laurence, and W. J. Johnson.
1995.
Neutrophils from human immunodeficiency virus (HIV)-seronegative donors induce HIV replication from HIV-positive patients' mononuclear cells and cell lines: an in vitro model of HIV transmission facilitated by Chlamydia trachomatis.
J. Exp. Med.
181:1493-1505[Abstract/Free Full Text].
|
| 16.
|
Ho, J. L.,
S. G. Reed,
J. Sobel,
S. Arruda,
S. H. He,
E. A. Wick, and K. H. Grabstein.
1992.
Interleukin-3 induces antimicrobial activity against Leishmania amazonensis and Trypanosoma cruzi and tumoricidal activity in human peripheral blood-derived macrophages.
Infect. Immun.
60:1984-1993[Abstract/Free Full Text].
|
| 17.
|
Ho, M.,
D. K. Koech,
D. W. Iha, and A. D. Bryceson.
1983.
Immunosuppression in Kenyan visceral leishmaniasis.
Clin. Exp. Immunol.
51:207-214[Medline].
|
| 18.
|
Huu, T. P.,
Y. Dumez,
C. Marquetty,
A. Durandy,
J. Boue, and J. Hakim.
1987.
Prenatal diagnosis of chronic granulomatous disease (CGD) in four high risk male fetuses.
Prenatal Diagn.
7:253-260[Medline].
|
| 19.
|
Kanaho, Y.,
K. Takahashi,
U. Tomita,
T. Iiri,
T. Katada,
M. Ui, and Y. Nozawa.
1992.
A protein kinase C inhibitor, staurosporine, activates phospholipase D via a pertussis toxin-sensitive GTP-binding protein in rabbit peritoneal neutrophils.
J. Biol. Chem.
267:23554-23559[Abstract/Free Full Text].
|
| 20.
|
Liew, F. Y.,
S. Millott,
C. Parkinson,
R. M. Palmer, and S. Moncada.
1990.
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine.
J. Immunol.
144:4794-4797[Abstract].
|
| 21.
|
Lima, G. M.,
A. L. Vallochi,
U. R. Silva,
E. M. Bevilacqua,
M. M. Kiffer, and I. A. Abrahamsohn.
1998.
The role of polymorphonuclear leukocytes in the resistance to cutaneous leishmaniasis.
Immunol. Lett.
64:145-151[CrossRef][Medline].
|
| 22.
|
Murray, H. W., and C. F. Nathan.
1999.
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani.
J. Exp. Med.
189:741-746[Abstract/Free Full Text].
|
| 23.
|
Paul, M.,
R. Durand,
H. Fessi,
D. Rivollet,
R. Houin,
A. Astier, and M. Deniau.
1997.
Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.
Antimicrob. Agents Chemother.
41:1731-1734[Abstract].
|
| 24.
|
Perianin, A.,
C. Combadiere,
E. Pedruzzi,
B. Djerdjouri, and J. Hakim.
1993.
Staurosporine stimulates phospholipase D activation in human polymorphonuclear leukocytes.
FEBS Lett.
315:33-37[CrossRef][Medline].
|
| 25.
|
Perianin, A.,
E. Pedruzzi, and J. Hakim.
1994.
W-7, a calmodulin antagonist, primes the stimulation of human neutrophil respiratory burst by formyl peptides and platelet-activating factor.
FEBS Lett.
342:135-138[CrossRef][Medline].
|
| 26.
|
Rais, S.,
E. Pedruzzi,
M. C. Dang,
J. P. Giroud,
J. Hakim, and A. Perianin.
1998.
Priming of phosphatidic acid production by staurosporine in f-Met-Leu-Phe-stimulated human neutrophils correlation with respiratory burst.
Cell. Signal.
10:121-129[CrossRef][Medline].
|
| 27.
|
Scott, P.
1989.
The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis.
Exp. Parasitol.
68:369-372[CrossRef][Medline].
|
| 28.
|
Stauber, L. A.,
E. M. Franchino, and J. Grun.
1958.
An eight day method for screening compounds against Leishmania donovani in golden hamster.
J. Protozool.
5:269-273.
|
| 29.
|
Tono-oka, T.,
T. Matsumoto,
N. Ueno,
N. Yashiki, and S. Matsumoto.
1983.
Chemiluminescence of whole blood. II. Application to clinical examination of phagocytic functions of whole blood from various types of disease.
Clin. Immunol. Immunopathol.
29:333-340[CrossRef][Medline].
|
| 30.
|
Vouldoukis, I.,
V. Riveros-Moreno,
B. Dugas,
F. Ouaaz,
P. Becherel,
P. Debre,
S. Moncada, and M. D. Mossalayi.
1995.
The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen.
Proc. Natl. Acad. Sci. USA
92:7804-7808[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, September 2000, p. 2406-2410, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
El Fadili, K., Imbeault, M., Messier, N., Roy, G., Gourbal, B., Bergeron, M., Tremblay, M. J., Legare, D., Ouellette, M.
(2008). Modulation of Gene Expression in Human Macrophages Treated with the Anti-Leishmania Pentavalent Antimonial Drug Sodium Stibogluconate. Antimicrob. Agents Chemother.
52: 526-533
[Abstract]
[Full Text]
-
Mookerjee Basu, J., Mookerjee, A., Sen, P., Bhaumik, S., Sen, P., Banerjee, S., Naskar, K., Choudhuri, S. K., Saha, B., Raha, S., Roy, S.
(2006). Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages.. Antimicrob. Agents Chemother.
50: 1788-1797
[Abstract]
[Full Text]
-
Dey, R., Sarkar, A., Majumder, N., Bhattacharyya (Majumdar), S., Roychoudhury, K., Bhattacharyya, S., Roy, S., Majumdar, S.
(2005). Regulation of Impaired Protein Kinase C Signaling by Chemokines in Murine Macrophages during Visceral Leishmaniasis. Infect. Immun.
73: 8334-8344
[Abstract]
[Full Text]
-
Sudhandiran, G., Shaha, C.
(2003). Antimonial-induced Increase in Intracellular Ca2+ through Non-selective Cation Channels in the Host and the Parasite Is Responsible for Apoptosis of Intracellular Leishmania donovani Amastigotes. J. Biol. Chem.
278: 25120-25132
[Abstract]
[Full Text]
-
Ghosh, M., Pal, C., Ray, M., Maitra, S., Mandal, L., Bandyopadhyay, S.
(2003). Dendritic Cell-Based Immunotherapy Combined with Antimony-Based Chemotherapy Cures Established Murine Visceral Leishmaniasis. J. Immunol.
170: 5625-5629
[Abstract]
[Full Text]
-
Kocyigit, A., Gur, S., Gurel, M. S., Bulut, V., Ulukanligil, M.
(2002). Antimonial Therapy Induces Circulating Proinflammatory Cytokines in Patients with Cutaneous Leishmaniasis. Infect. Immun.
70: 6589-6591
[Abstract]
[Full Text]
-
Mukherjee, S. B., Das, M., Sudhandiran, G., Shaha, C.
(2002). Increase in Cytosolic Ca2+ Levels through the Activation of Non-selective Cation Channels Induced by Oxidative Stress Causes Mitochondrial Depolarization Leading to Apoptosis-like Death in Leishmania donovani Promastigotes. J. Biol. Chem.
277: 24717-24727
[Abstract]
[Full Text]